This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CX3CR1 / CX3C chemokine receptor 1 · IHC design guide
Design Immunohistochemistry for CX3CR1
Plan chromogenic CX3CR1 IHC on paraffin sections using the catalog antibody's human tissue evidence (datasheet A00280-2). Assess cell type and staining compartment, keeping HPA's low agreement between staining and RNA expression in mind (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CX3CR1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); cell membrane location (UniProt) | |
| Staining pattern | Cytoplasmic staining in several tissues, including cerebral cortex (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A00280-2) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00280-2) | |
| Caveat | Antibody staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Inflammation can change recruited cell populations (UniProt) | |
| Isoform / epitope | Four isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt) |
Section 1
Recommended CX3CR1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet: A00280-2) with four published chromogenic IHC protocols (PMC3921448; PMC3399807; PMC5471565; PMC3730155).
| Sample | Paraffin-embedded human adenocarcinoma of the right colon tissue; fixative not specified (datasheet A00280-2) |
| Fixation | Image fixative and duration unreported (datasheet A00280-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A00280-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00280-2) |
| Primary antibody | Rabbit anti-CX3CR1, 2-5 μg/ml (datasheet A00280-2) |
| Primary incubation | Overnight at 4 °C (datasheet A00280-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A00280-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CX3CR1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in several tissues, including cerebral cortex. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet: A00280-2); citrate at pH 6.0 is a published alternative for artery sections (PMC3399807).
Section 2
What Is the Expected CX3CR1 Staining Pattern?
CX3CR1 is a seven-pass cell-membrane receptor (UniProt P49238 topology). Expect staining associated with cells that express it, including lymphocyte subsets described by UniProt (UniProt P49238 tissue specificity). In tissue sections, HPA reports cytoplasmic staining in several tissues, including cerebral cortex, but rates its IHC profile Approved with low consistency between staining and RNA expression (HPA tissue IHC). Interpret compartment and cell identity together.
| Defined staining at cell outlines, with possible cytoplasmic staining in tissue sections. | Membrane association fits the receptor topology and the supported plasma-membrane ICC-IF location (UniProt P49238 topology; HPA subcellular). Cytoplasmic staining can also resemble HPA's tissue IHC profile; it needs cell-level and control assessment rather than automatic rejection (HPA tissue IHC). |
| Predominantly nuclear staining, without a convincing membrane or cell-associated pattern. | A nuclear pattern lacks support from the supplied CX3CR1 locations (UniProt P49238 subcellular; HPA subcellular). Consider nonspecific detection or an interpretation artefact; compare the stained section with a matched negative control and inspect whether the signal follows nuclei or cell borders (general IHC practice). |
| Strong staining in a population HPA records as not detected, such as adipocytes or bronchial respiratory epithelium. | That result conflicts with the reported cell-specific tissue observations (HPA tissue IHC). Check cell identification and controls before attributing it to CX3CR1; antibody cross-reactivity or endogenous detection activity are possible technical explanations (general IHC practice). An HPA negative observation is a comparator, not proof that every specimen is negative. |
| Uniform haze or widespread colour over tissue and empty areas. | A diffuse field obscures whether signal belongs to cells with a plausible CX3CR1 pattern (UniProt P49238 topology; HPA tissue IHC). Review blocking, antibody concentration, washes and chromogen development with the detection controls; these are general IHC background checks, not documented CX3CR1-specific effects (general IHC practice). |
| No discernible staining in a positive comparison section, such as appendix glandular cells. | HPA reports medium staining in appendix glandular cells, so an absent signal merits a workflow check (HPA tissue IHC). Verify section quality, retrieval conditions, antibody and detection reagents against the applicable protocol (general IHC practice). HPA's low staining-to-RNA consistency limits how strongly one tissue result can validate specificity (HPA tissue IHC). |
💡Expected CX3CR1 appearanceA credible positive is cell-associated staining compatible with a membrane receptor (UniProt P49238 topology; HPA subcellular), potentially with cytoplasmic tissue staining of medium intensity in HPA-listed cells such as appendix glandular cells (HPA tissue IHC); isolated nuclear colour or uniform haze warrants control-based review (general IHC practice).
| Compartment and epitope orientation | CX3CR1 has seven membrane-spanning segments and both extracellular and cytoplasmic regions (UniProt P49238 topology). Interpret a particular antibody's pattern in light of its documented epitope, if known; the supplied record does not locate that epitope. |
| Tissue and cell selection | HPA reports medium staining in several glandular populations and caudate glial cells, but no detected staining in specified adipocytes, bronchial respiratory epithelium and other listed populations (HPA tissue IHC). Compare the same cell type, not whole-tissue colour. |
| Evidence agreement | HPA rates tissue IHC Approved while reporting low consistency between antibody staining and RNA expression (HPA tissue IHC). Treat a matching image as supportive pattern evidence, and assess specificity with controls rather than using staining intensity alone (general IHC practice). |
| Isoforms and processing | UniProt lists four CX3CR1 isoforms and a single receptor chain spanning residues 1–355, with no signal peptide or propeptide annotated (UniProt P49238 isoforms; processing). The supplied sources give no isoform-specific IHC pattern or shedding claim. |
| Detection system | Endogenous enzyme activity can mimic chromogenic signal, depending on the detection chemistry (general IHC practice). Use the appropriate detection-only control to distinguish that activity from antibody-dependent staining; the supplied sources do not identify a CX3CR1-specific interference. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in an HPA medium-staining comparison cell type. | The run may have weak antigen detection, or the sampled cells may differ from the HPA example (HPA tissue IHC; general IHC practice). | Confirm cell identity, then check retrieval, antibody dilution and detection steps against the antibody's IHC-P protocol; include a run control (general IHC practice). |
| Staining appears mainly nuclear. | Nuclear localisation is unsupported by the supplied membrane-location evidence (UniProt P49238 subcellular; HPA subcellular). | Compare with a negative control and review counterstain and colour separation before scoring the signal as CX3CR1 (general IHC practice). |
| Strong signal appears in HPA-listed negative cell populations. | Cell misidentification, cross-reactivity or endogenous detection activity could explain a mismatch with HPA observations (HPA tissue IHC; general IHC practice). | Recheck the cell type, use an antibody-omission or detection-only control, and compare with a listed positive population (general IHC practice; HPA tissue IHC). |
| Background is diffuse across the section. | Nonspecific antibody binding, inadequate washing or excessive colour development can reduce contrast (general IHC practice). | Review blocking, dilution, washes and development time one variable at a time; judge improvement against the same control section (general IHC practice). |
| Cytoplasmic staining seems at odds with a membrane receptor. | HPA describes cytoplasmic tissue IHC staining, while UniProt and HPA ICC-IF support membrane localisation (HPA tissue IHC; UniProt P49238 subcellular; HPA subcellular). | Record both the compartment and cell type, compare with HPA tissue examples, and avoid treating cytoplasmic colour alone as proof of specificity (HPA tissue IHC; general IHC practice). |
| IF/ICC shows a different compartment from tissue IHC. | HPA reports supported plasma-membrane localisation by ICC-IF and cytoplasmic staining in tissue IHC; these observations come from different applications (HPA subcellular; HPA tissue IHC). | Interpret IF/ICC on its own guide page and compare application-specific controls and images; do not transfer an IF/ICC result into an IHC-P protocol choice (general IHC practice). |
Experiment evidence
IHC & IF images showing CX3CR1 staining
A00280-2 · IHCIHC analysis of CX3CR1 using anti-CX3CR1 antibody (A00280-2). CX3CR1 was detected in a paraffin-embedded section of human adenocarcinoma of
A00280-2 · IHCIHC analysis of CX3CR1 using anti-CX3CR1 antibody (A00280-2). CX3CR1 was detected in a paraffin-embedded section of human liver cancer tissu
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000168329-CX3CR1/tissue/cerebral+cortex#imid_17237363
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000168329-CX3CR1/tissue/colon#imid_17237297
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000168329-CX3CR1/tissue/liver#imid_17237298
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000168329-CX3CR1/tissue/kidney#imid_17237291
HPA · ICC-IF HELHuman Protein Atlas immunofluorescence, HEL, antibody HPA046587; green = CX3CR1, blue = nucleus, red = microtubules.
HPA · ICC-IF HELHuman Protein Atlas immunofluorescence, HEL, antibody HPA046587; green = CX3CR1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CX3CR1 IHC & IF
🧪Run colon first and look for staining in glandular cells (HPA: Medium in colon glandular cells). Use adipose tissue as the negative comparator and assess adipocytes, which are listed as not detected (HPA: Not detected in adipocytes); on the colon slide, cells outside the stained glandular population should remain unstained, without assuming every nonglandular cell is negative (HPA: Medium in colon glandular cells; UniProt P49238: expression in immune cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CX3CR1 in HEL, THP-1, U2OS, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a concentration-matched nonimmune rabbit IgG control, and a verified CX3CR1 knockout sample or validated immunizing-peptide block (selected-SKU caption: rabbit primary antibody; standard IHC control practice). Block endogenous peroxidase and assess background in colon before interpreting DAB signal (selected-SKU caption: colon section with HRP/DAB detection; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the fixative in the selected A00280-2 tissue-IHC caption is unreported (selected-SKU caption: fixative not stated). The reported paraffin-section result used heat retrieval in EDTA at pH 8.0, followed by 2 μg/ml primary antibody overnight at 4°C; this documents a working retrieval condition, not that retrieval is required for all specimens (selected-SKU caption). Frozen sections and IF/ICC are not established as easier by the supplied IHC evidence; for colon IHC, distinguish specific staining from endogenous peroxidase background (HPA: plasma membrane localization supported by ICC-IF; selected-SKU caption: colon HRP/DAB staining; standard IHC practice).
HPA tissue IHC evidence for CX3CR1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
| Colon | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CX3CR1 IHC Tips
Troubleshoot CX3CR1 staining in paraffin sections by checking retrieval, cellular compartment, controls and scoring before interpreting chromogenic signal.
How should I retrieve CX3CR1 when staining paraffin sections?
Start with heat-mediated retrieval in EDTA, pH 8.0, for paraffin sections (datasheet A00280-2). The catalog antibody produced CX3CR1 staining in a paraffin section of human right-colon adenocarcinoma after that retrieval, followed by 2 μg/ml primary antibody overnight at 4°C (datasheet A00280-2). If staining is weak, check heating uniformity and section adhesion before changing retrieval conditions; compare any adjustment with the original condition on adjacent sections. Keep antibody concentration, detection chemistry and development time constant during that comparison so a retrieval change is the main variable.
Could fixation explain weak or uneven CX3CR1 staining?
The selected tissue-IHC caption describes a paraffin section but does not state its fixative, so target-specific fixation sensitivity is unknown (datasheet A00280-2). Record each specimen’s fixative and fixation duration, then compare sections processed under the same conditions; avoid attributing a difference to CX3CR1 biology until processing is matched. Check whether weak staining tracks thick sections, incomplete deparaffinisation or uneven retrieval, using the documented EDTA, pH 8.0 method as the starting condition (datasheet A00280-2). If archived blocks differ in processing history, report that limitation beside any comparison of staining intensity; neither tissue-IHC patterns nor receptor topology establishes a fixation effect.
Should CX3CR1 appear on the membrane or in the cytoplasm?
Prioritise staining at cell borders: CX3CR1 is annotated at the cell membrane (UniProt P49238), and plasma-membrane localisation is supported by subcellular imaging (HPA subcellular). The receptor has 7 transmembrane segments, so resolve the stained compartment at high magnification before scoring a faint diffuse signal as receptor positive (UniProt P49238 topology). Tissue IHC also reports cytoplasmic staining in several tissues, including cerebral cortex, but its staining and RNA data have low consistency (HPA tissue IHC). Score membrane and cytoplasmic signal separately, and treat isolated diffuse cytoplasmic staining as uncertain until controls and cell identity support it.
How does epitope position affect CX3CR1 staining in sections?
CX3CR1 has 4 annotated isoforms, while the supplied catalog caption does not identify the antibody’s epitope or establish isoform coverage (UniProt P49238; datasheet A00280-2). Its N-terminal residues 1–31 are extracellular, and its C-terminal residues 298–355 are cytoplasmic (UniProt P49238 topology). Check the antibody’s mapped immunogen against the isoform sequences before interpreting staining differences as isoform expression. If the epitope remains unmapped, report staining as CX3CR1 immunoreactivity rather than isoform-specific detection, and avoid assigning a failed stain to epitope loss without a comparison using a distinct, documented epitope.
How should I investigate CX3CR1 localisation by multiplex immunofluorescence?
For a separate IF experiment, multiplex CX3CR1 with an independently validated marker of the expected cell type, such as a marker selected for the immune population under study (UniProt P49238 tissue specificity). Include single-label controls and choose a far-red channel for a dim signal when tissue autofluorescence is stronger at shorter wavelengths. Determine permeabilisation from the mapped epitope: an extracellular N-terminal epitope may be accessible without it, whereas a cytoplasmic C-terminal epitope requires access across the membrane (UniProt P49238 topology). Evaluate apparent colocalisation against the supported plasma-membrane location and confirm that the cell-type marker occupies the intended cells (HPA subcellular).
What should I check when CX3CR1 DAB staining is widespread?
First compare the stained section with a primary-antibody omission control and inspect whether DAB appears in the same structures. The catalog tissue example used 10% goat-serum blocking, a peroxidase-conjugated secondary and DAB development; those are documented conditions for that image (datasheet A00280-2). Include a peroxidase block in the general chromogenic workflow, and check whether excessive DAB development or nonspecific secondary binding accounts for the widespread colour. Reassess concentrated or diffuse signal against the supported plasma-membrane localisation, keeping in mind the reported low consistency between tissue staining and RNA expression (HPA subcellular; HPA tissue IHC).
How can I quantify CX3CR1 across sections with different cell mixtures? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and cell population before measuring CX3CR1, using membrane localisation as the primary anatomical reference (UniProt P49238; HPA subcellular). For a relatively uniform population, record % positive cells and an intensity-based H-score; for scattered positive cells, report their density per mm² of evaluable tissue. Normalise counts to the relevant cell population or sampled tissue area, and record how much necrotic or damaged area was excluded. Use the same threshold, magnification, sampling plan and DAB development conditions across sections; report membrane and cytoplasmic scores separately because tissue staining includes cytoplasmic expression (HPA tissue IHC).
When is CX3CR1 staining convincing rather than an artefact?
A convincing result has reproducible signal in morphologically identifiable cells, with cell-border staining consistent with the receptor’s membrane annotation (UniProt P49238; HPA subcellular). Consider the sampled tissue and cell type: reported expression includes selected lymphocyte subsets, and tissue IHC shows glial staining in caudate (UniProt P49238 tissue specificity; HPA tissue IHC). Be cautious with signal confined to section edges, necrotic regions or the primary-antibody omission control; inspect these patterns before calling cells positive. Widespread cytoplasmic DAB alone warrants additional validation because the tissue-IHC profile reports cytoplasmic staining but low consistency with RNA expression (HPA tissue IHC).
Boster reagents
Best CX3CR1 / CX3C chemokine receptor 1 IHC Antibodies
The IHC-validated anti-CX3CR1 antibody has paraffin-section images from human right-colon adenocarcinoma, liver cancer, and lymphoma (A00280-2 image captions). No IF image is supplied (catalog).
Real IHC data
Anti-CX3CR1 Antibody
Cat # A00280-2
A00280-2 is listed for human IHC, flow cytometry, and ELISA (catalog: applications and reactivity). Its IHC captions show paraffin sections of human right-colon adenocarcinoma, liver cancer, and lymphoma (A00280-2 image captions).
Which to pick: Choose the rabbit polyclonal A00280-2 for human paraffin-section IHC; its caption documents EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody, while the datasheet lists 2–5 μg/ml for IHC (catalog; A00280-2 image caption; datasheet). The caption does not report the fixative (A00280-2 image caption). No listed SKU has IF/ICC validation or reactivity beyond human, so this catalog offers no supported IF/ICC or cross-species pick (catalog: applications and reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P49238 (CX3C1_HUMAN, CX3C chemokine receptor 1).
- Human Protein Atlas. CX3CR1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. CX3CR1 subcellular location (ICC-IF): Localized to the plasma membrane..
- Human Protein Atlas. CX3CR1 antibody validation summary (2 antibodies).
- CX3CL1 (fractalkine) and TNFα production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2014 — PMC3921448.
- Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression. PloS one 2012 — PMC3399807.
- High Glucose Level Disturbs the Resveratrol-Evoked Curtailment of CX3CL1/CX3CR1 Signaling in Human Placental Circulation. Mediators of inflammation 2017 — PMC5471565.
- Fractalkine (CX3CL1) and its receptor CX3CR1 may contribute to increased angiogenesis in diabetic placenta. Mediators of inflammation 2013 — PMC3730155.
- PubMed PMID:7590284 — UniProt-cited evidence.
- PubMed PMID:7646814 — UniProt-cited evidence.
- PubMed PMID:12551893 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CX3CR1 (CX3C chemokine receptor 1). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); cell membrane location (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A00280-2). Validated IHC antibody: A00280-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human adenocarcinoma of the right colon tissue; fixative not specified (datasheet A00280-2); 2. Fixation: Image fixative and duration unreported (datasheet A00280-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A00280-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00280-2); 8. Primary antibody: Rabbit anti-CX3CR1, 2-5 μg/ml (datasheet A00280-2); 9. Primary incubation: Overnight at 4 °C (datasheet A00280-2). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00280-2); Caveat: Antibody staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: Four isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt); Regulation: Inflammation can change recruited cell populations (UniProt). Evidence: UniProt P49238, HPA tissue IHC · Approved, HPA ICC-IF · plasma membrane., Datasheet A00280-2, PMC3921448, PMC3399807. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CX3CR1/immunohistochemistry-ihc-guide.